Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188146 | 0.91 | LMNA (0.54) | KMT2ATRPV1HDAC1HDAC2HDAC3 | |
| SCHEMBL4187918 | 0.90 | HDAC1 (0.53) | KMT2AMEN1ALDH1A1FADS1TRPV1 | |
| SCHEMBL13653256 | 0.89 | HDAC1 (0.50) | KMT2ATRPV1HDAC1HDAC2HDAC3 | |
| SCHEMBL4185425 | 0.88 | KMT2A (0.58) | KMT2AMEN1ALDH1A1TRPV1NPC1 | |
| SCHEMBL4189753 | 0.88 | TAS1R3 (0.58) | KMT2AMEN1ALDH1A1NPC1RAB9A | |
| SCHEMBL4182629 | 0.88 | HDAC1 (0.46) | KMT2AALDH1A1TRPV1NPC1RAB9A | |
| SCHEMBL4193646 | 0.87 | ALDH1A1 (0.48) | KMT2AMEN1ALDH1A1TRPV1HDAC1 | |
| SCHEMBL13653257 | 0.87 | TAS1R3 (0.56) | TRPV1NPC1RAB9AHDAC1HDAC2 | |
| SCHEMBL4190602 | 0.87 | HDAC1 (0.54) | KMT2AMEN1ALDH1A1TRPV1HDAC1 | |
| SCHEMBL4197796 | 0.87 | HDAC3 (0.50) | ALDH1A1TRPV1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | KMT2A 1662/4885MEN1 612/4885ALDH1A1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.